
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1064 | 1061 | 1167 | 1184 | 1378 | 2389 |
Fund Return | 6.37% | 6.12% | 16.67% | 5.78% | 6.62% | 9.1% |
Place in category | 673 | 502 | 45 | 10 | 38 | 8 |
% in Category | 89 | 68 | 8 | 2 | 10 | 3 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 8.24B | 0.98 | 11.71 | 12.36 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.32B | 2.19 | 10.23 | 9.88 | ||
UBS CH Vitainvest 50 World U | 4.27B | 7.32 | -1.50 | 2.35 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.9B | 3.63 | 3.95 | 8.17 | ||
UBS CH Institutional Fund 2 EquiSCB | 2.9B | 3.63 | 3.89 | 8.11 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.69B | 12.09 | 5.90 | 7.10 | ||
Pictet CH Institutional Swiss EquZD | 2.26B | 10.28 | 3.87 | 7.82 | ||
Pictet CH Institutional Swiss EquiZ | 2.26B | 8.90 | 2.54 | 8.57 | ||
Pictet CH Institutional Swiss EquiI | 2.26B | 8.86 | 2.05 | 8.05 | ||
Pictet CH Institutional Swiss EquiP | 2.26B | 8.84 | 1.85 | 7.84 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 9.22 | 90.24 | 0.00% | |
Roche Holding Participation | CH0012032048 | 9.14 | 311.40 | +0.10% | |
Novartis | CH0012005267 | 8.86 | 98.52 | -0.08% | |
UBS Group | CH0244767585 | 8.82 | 29.55 | +0.89% | |
Zurich Insurance Group | CH0011075394 | 8.59 | 609.40 | +0.43% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review